Analysts reiterate ratings on Ancestry.com Inc (NASDAQ: ACOM), Aetna Inc. (NYSE: AET), Biomarin Pharm (NASDAQ: BMRN), Calix Networks (NASDAQ: CALX) and Caterpillar Inc. (NYSE: CAT).
Piper Jaffray (NYSE:PJC) reiterated an “overweight” rating on Ancestry.com Inc (ACOM).
JPMorgan Chase & Co. (NYSE:JPM) reiterated an “overweight” rating on Aetna Inc. (AET). They have a price target of $46.00 on the company, up from $43.00.
JPMorgan Chase & Co. reiterated an “overweight” rating on Biomarin Pharm (BMRN).
Jefferies (NYSE:JEF) reiterated a “buy” rating on Calix Networks (CALX).
Jefferies reiterated a “buy” rating on Caterpillar Inc. (CAT). They now have a $125.00 price target on the company.
Showing posts with label BioMarin. Show all posts
Showing posts with label BioMarin. Show all posts
Friday, April 29, 2011
Thursday, March 10, 2011
Biotech Doesn't Get Human Genome (HGSI) Bump
Negative economic news is weighing on the markets today, and even with the nice performance of Human Genome Sciences (NASDAQ:HGSI), it wasn't enough to push the sector up with them.
Human Genome Sciences was jumping over 12 percent after the FDA approved the company's Benlysta drug for the treatment of lupus. The drug is the first designed specifically to treat lupus, an incurable condition, afflicting 1.5 million Americans and 5 million people worldwide, Bloomberg News reported. GlaxoSmithKline (NYSE:GSK) is partnering with Human Genome Sciences on Benlysta. One analyst cited by Bloomberg said Benlysta sales could reach $2.3 billion in the U.S. and $3.6 billion globally in 2015.
The companies expect to have Benlysta available to doctors within two weeks, according to Human Genome.
Biomarin Pharmaceutical (NASDAQ:BMRN) is down 2% today. Biogen Idec (NASDAQ:BIIB) is lower by 1%. Both had unsuccessfully attempted to bring lupus treatments to the market in the past.
In other parts of the biotech sector, Transition Therapeutics (NASDAQ:TTHI) is plummeting 16% on high volume. Spectrum Pharmaceuticals (NASDAQ:SPPI) and Exelixis (NASDAQ:EXEL) are also trading at higher-than-normal volumes.
Human Genome was trading at $28.91, gaining $3.23, or 12.58 percent, as of 1:42 PM EST.
Human Genome Sciences was jumping over 12 percent after the FDA approved the company's Benlysta drug for the treatment of lupus. The drug is the first designed specifically to treat lupus, an incurable condition, afflicting 1.5 million Americans and 5 million people worldwide, Bloomberg News reported. GlaxoSmithKline (NYSE:GSK) is partnering with Human Genome Sciences on Benlysta. One analyst cited by Bloomberg said Benlysta sales could reach $2.3 billion in the U.S. and $3.6 billion globally in 2015.
The companies expect to have Benlysta available to doctors within two weeks, according to Human Genome.
Biomarin Pharmaceutical (NASDAQ:BMRN) is down 2% today. Biogen Idec (NASDAQ:BIIB) is lower by 1%. Both had unsuccessfully attempted to bring lupus treatments to the market in the past.
In other parts of the biotech sector, Transition Therapeutics (NASDAQ:TTHI) is plummeting 16% on high volume. Spectrum Pharmaceuticals (NASDAQ:SPPI) and Exelixis (NASDAQ:EXEL) are also trading at higher-than-normal volumes.
Human Genome was trading at $28.91, gaining $3.23, or 12.58 percent, as of 1:42 PM EST.
Tuesday, February 1, 2011
Alexion (NASDAQ:ALXN), Cadence (NASDAQ:CADX), Cubist (NASDAQ:CBST), Dendreon (NASDAQ:DNDN), Human Genome (NASDAQ:HGSI) Could be Takeover Targets
With time and costs a major factor in the drug industry, companies appear to be hunting for takeover targets like Alexion (NASDAQ:ALXN), Cadence (NASDAQ:CADX), Cubist (NASDAQ:CBST), Dendreon (NASDAQ:DNDN) and Human Genome (NASDAQ:HGSI), which have a pipeline, or are close to developing a pipeline, with soon-to-be-approved drugs.
Others noted in a recent Barron's article as possible takeover candidates were Acorda (NASDAQ:ACOR), AMAG Pharmaceuticals (NASDAQ:AMAG), BioMarin (NASDAQ:BMRN), Cephalon (NASDAQ:CEPH), Jazz Pharma (NASDAQ:JAZZ), Onyx (NASDAQ:ONXX), United Therapeutics (NASDAQ:UTHR), and Salix Pharmaceuticals (NASDAQ:SLXP).
Some of the companies rose on the assertions, with Cadence closing Monday at $7.76, gaining $0.47, or 6.52 percent.
Others noted in a recent Barron's article as possible takeover candidates were Acorda (NASDAQ:ACOR), AMAG Pharmaceuticals (NASDAQ:AMAG), BioMarin (NASDAQ:BMRN), Cephalon (NASDAQ:CEPH), Jazz Pharma (NASDAQ:JAZZ), Onyx (NASDAQ:ONXX), United Therapeutics (NASDAQ:UTHR), and Salix Pharmaceuticals (NASDAQ:SLXP).
Some of the companies rose on the assertions, with Cadence closing Monday at $7.76, gaining $0.47, or 6.52 percent.
Subscribe to:
Posts (Atom)